SynthesisJournal of global health2026
Global, regional, and national prevalence of pterygium in 2023: a systematic review and modelling analysis.
Synthesis in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pterygium contributes to otherwise avoidable vision loss and reduced quality of life worldwide. Despite its treatability and the availability of low-cost interventions, it is often overlooked in global health strategies. We aimed to estimate global, regional, and national pterygium prevalence and examine variations in prevalence by age and sex. Methods: We systematically searched PubMed, Embase, and MEDLINE for articles reporting on the prevalence of pterygium published from 1 January 1990 to 25 September 2024. For China-specific data, we supplemented this search with articles included in a prior systematic review and meta-analysis, and an updated search of four Chinese databases (CNKI, Wanfang, CBM, and VIP) from 1 January 2016 to 25 September 2024. We developed multilevel multivariable mixed-effects meta-regression models to estimate the global, regional, and national age- and sex-specific prevalences of pterygium in 2023, and an associated factor-based model to adjust national prevalence estimates. Results: We included 103 articles for analysis. The global prevalence of pterygium was 8.22% (95% confidence interval (CI) = 5.31-12.43) in 2023, amounting to 552.85 million (95% CI = 356.93-835.74) cases. We observed that the prevalence increased with age, and that it did not differ substantially by sex, i.e. among men (8.36%; 95% CI = 5.40-12.63) and women (8.08%; 95% CI = 5.21-12.22). We found the highest regional prevalence of pterygium in low- and middle-income countries of the South-East Asia Region (13.52%; 95% CI = 8.98-19.65) in 2023, and the highest national prevalence in Saint Helena (22.57%; 95% CI = 11.79-39.47). Conclusions: Our analysis indicates that pterygium represents a substantial global burden that can progress to severe visual impairment if untreated. Targeted public health strategies are urgently needed to prevent pterygium-related vision loss worldwide. Registration: PROSPERO: CRD420251056115.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.